Urinary detection times and metabolite/parent compound ratios after a single dose of buprenorphine

Journal of Analytical Toxicology

Volumn 32, Issue 8, 2008, Pages 586-593

  Kronstrand, Robert ^a,d   Nyström, Ingrid ^a   Andersson, Malin ^a   Gunnarsson, Lina ^a   Hägg, Staffan ^b,c   Josefsson, Martin ^a   Ahlner, Johan ^a  

^a DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d National Board of Forensic Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CREATININE; NORBUPRENORPHINE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG EXCRETION; DRUG URINE LEVEL; ENZYME IMMUNOASSAY; FEMALE; HEADACHE; HEARING IMPAIRMENT; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NAUSEA AND VOMITING; NORMAL HUMAN; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; TANDEM MASS SPECTROMETRY; TREMOR; URINALYSIS; VERTIGO; XEROSTOMIA;

EID: 56449112183     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.8.586     Document Type: Article

References (25)

1. J. Kakko, L. Gronbladh, K.D. Svanborg, J. von Wachenfeldt, C. Ruck, B. Rawlings, L.H. Nilsson, and M. Heilig. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am. J. Psychiatry 164(5): 797-803 (2007).
2. J. Kakko, K.D. Svanborg, M.J. Kreek, and M. Heilig. One-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361(9358): 662-668 (2003).
3. M.Z. Mintzer, C.J. Correia, and E.C. Strain. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend. 74(2): 205-209 (2004).
4. J. Mendelson and R.T. Jones. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend. 70(2S): S29-S37 (2003).
5. A. Elkader and B. Sproule. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44(7): 661-680 (2005).
6. E.J. Cone, C.W. Gorodetzky, D. Yousefnejad, W.F. Buchwald, and R.E. Johnson. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5): 577-581 (1984).
7. E.J. Fox, V.A. Tetlow, and K.R. Allen. Quantitative analysis of buprenorphine and norbuprenorphine in urine using liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 30(4): 238-244 (2006).
8. Y. Blom, U. Bondesson, and E. Anggard. Analysis of buprenorphine and its n-dealkylated metabolite in plasma and urine by selected ion monitoring. J. Chromatogr. B 338: 89-98 (1985).
9. S. Hegstad, H.Z. Khiabani, E.L. Oiestad, T. Berg, and A.S. Christophersen. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. J. Anal. Toxicol. 31(4): 214-219 (2007).
10. W. Huang, D.E. Moody, and E.F. McCance-Katz. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 28(2): 245-251 (2006).
11. R. Kronstrand, T.G. Selden, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27(7): 464-470 (2003).
12. S. Feng, M.A. ElSohly, and D.T. Duckworth. Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 25(7): 589-593 (2001).
13. A.M. Lisi, R. Kazlauskas, and G.J. Trout. Gas chromatographic-mass spectrometric quantitation of urinary buprenorphine and norbuprenorphine after derivatization by direct extractive alkylation. J. Chromatogr. B Biomed. Sci. Appl. 692(1): 67-77 (1997).
14. F. Vincent, J. Bessard, J. Vacheron, M. Mallaret, and G. Bessard. Determination of buprenorphine and norbuprenorphine in urine and hair by gas chromatography-mass spectrometry. J. Anal. Toxicol. 23(4): 270-279 (1999).
15. M. Bottcher and O. Beck. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J. Anal. Toxicol. 29(8): 769-76 (2005).
16. S. George, C. George, and M. Chauhan. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. Forensic Sci. Int. 143(2-3): 121-125 (2004).
17. M.A. ElSohly, W. Gul, S. Feng, and T.P. Murphy. Hydrolysis of conjugated metabolites of buprenorphine II. The quantitative enzymatic hydrolysis of norbuprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 29(6): 570-573 (2005).
18. Z. Lin, P. Lafolie, and O. Beck. Evaluation of analytical procedures for urinary codeine and morphine measurements. J. Anal. Toxicol. 18(3): 129-133 (1994).
19. P. Wang, J.A. Stone, K.H. Chen, S.F. Gross, C.A. Haller, and A.H. Wu. Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites. J. Anal. Toxicol. 30(8): 570-575 (2006).
20. V. Cirimele, P. Kintz, S. Lohner, and B. Ludes. Enzyme immunoassay validation for the detection of buprenorphine in urine. J. Anal. Toxicol. 27(2): 103-105 (2003).
21. A. Tracqui, P. Kintz, and B. Ludes. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 22(6): 430-434 (1998).
22. P. Kintz. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 121(1-2): 65-69 (2001).
23. M. Reynaud, G. Petit, D. Potard, and P. Courty. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 93(9): 1385-1392 (1998).
24. P. Kintz. A new series of 13 buprenorphine-related deaths. Clin. Biochem. 35(7): 513-516 (2002).
25. T. Seldén, M. Roman, G. Thelander, H. Druid, and R. Kronstrand. Buprenorphine concentrations in post mortem whole blood and urine from suspected overdose cases. Presented at the Society of Forensic Toxicologists Annual Meeting, Raleigh, NC, 2007.